Anthropic's AI drug discovery lead talks partnerships and pipeline

Endpoints News reports that Nathan Frey, who now leads drug discovery and development research at Anthropic, has remained active since the company acquired his biotech startup, Coefficient Bio, this past spring. Frey previously worked as a machine-learning scientist at Genentech before founding Coefficient Bio.

According to the outlet’s exclusive interview, Frey discussed his work building out biopharma partnerships under Anthropic’s banner, along with questions of mergers and acquisitions activity in the sector and the pipeline of projects his team is pursuing. Endpoints News frames the conversation as a rare glimpse into how a major AI company is approaching drug discovery from the inside, given Frey’s dual background in both computational science and biotech entrepreneurship.

The report notes that Frey’s trajectory, from an industry pharmaceutical research post to founding his own startup to his current role steering research at a large technology firm, reflects a broader pattern of AI companies absorbing specialized biotech talent and infrastructure. The interview is described as addressing how Anthropic intends to structure its relationships with pharmaceutical partners going forward, as well as Frey’s perspective on consolidation trends among firms applying machine learning to drug development.

The published account does not elaborate further on specific deal terms, named partners, or pipeline details beyond confirming that these topics were addressed. Endpoints News presents the piece as an exclusive, with publication dated October 30.